Market Overview:
The global diabetic peripheral neuropathy treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising awareness about diabetic peripheral neuropathy treatment options, and technological advancements in the field of diabetic peripheral neuropathy treatment. Based on type, the global diabetic peripheral neuropathy treatment market is segmented into antimunocels, ASP-8477s, BNV-222s, capsaicins, CBX-129801s and others. The antimunocel segment is expected to account for the largest share of the global diabetic peripheral neuropathy treatment market in 2018 owing to its high efficacy and safety profile. Based on application, the hospital segment is expected to account for the largest share of the global diabetic peripheral neurophytreatment market in 2018 owing to increased access to healthcare facilities and rising awareness about available treatments options among patients with diabetes mellitus (DM).
Product Definition:
Diabetic peripheral neuropathy treatment is the management of diabetic neuropathy, a group of symptoms that may develop in people with diabetes. Symptoms can include numbness or tingling in the feet and hands, pain, muscle weakness, and problems with balance and coordination. Treatment may include medications to control blood sugar levels or nerve pain relief medication. Exercising regularly and maintaining a healthy weight are also important for managing neuropathy symptoms.
Antimunocel:
Antimunocel is a regenerative medicine that helps in repairing and healing the damaged nerves in the body. It also helps to improve blood circulation and nerve function. The product has been proven to be effective for diabetic peripheral neuropathy (DPN) patients, who experience pain in feet, legs or arms due to diabetes.
ASP-8477:
ASP-8477 is a novel oral drug developed by the pharmaceutical company Merck KGaA. It is an acetylated version of the well-known anti-inflammatory drugs called asokine. The drug has been tested in phase II for treating diabetic peripheral neuropathy (DPN) and was found to have similar efficacy to Lopinavir/Ritonavir, which is used for treatment of HIV infection.
Application Insights:
Based on application, the market is segmented into hospital, clinic and others. The hospital segment dominated the market in 2017 owing to a high prevalence of diabetes and rising awareness about NP-Injectable drugs for diabetic peripheral neuropathy treatment. According to WHO, currently more than 400 million people are suffering from diabetes worldwide while approximately 663 million people were diagnosed with the disease in 2018. Thus, increasing number of patients suffering from diabetic peripheral neuropathy is expected to drive demand for Diabetic Peripheral Neuropathy Treatment during forecast period.
The clinic segment is anticipated to witness lucrative growth over the forecast period due largely by factors such as availability of advanced diagnostic tools that help detect early stages of DPN at an affordable cost along with favorable reimbursement policies that encourage diagnosis and treatment at clinics rather than hospitals or other healthcare facilities will also boost demand for Diabetic Peripheral Neuropathy Treatment during forecast years.
Regional Analysis:
North America dominated the global diabetic peripheral neuropathy treatment market in 2017. This can be attributed to the local presence of key players, high patient awareness levels coupled with a large base of target population in this region. The U.S.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to an increase in government initiatives pertaining to development of healthcare infrastructure along with rising disposable income especially after implementation of Goods & Services Tax (GST) system throughout India from July 2018 has created ample opportunities for various industry participants including pharmaceutical companies as well as medical device manufacturers/suppliers.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily because of the changing lifestyle and dietary habits. As a result, the number of people suffering from diabetic peripheral neuropathy is also on the rise. This provides a major growth driver for the diabetic peripheral neuropathy treatment market.
- Growing awareness about diabetic peripheral neuropathy: There is growing awareness among people about diabetic peripheral neuropathy and its symptoms. This has led to an increase in the number of people seeking treatment for this condition. This provides a major growth driver for the market.
Scope Of The Report
Report Attributes
Report Details
Report Title
Diabetic Peripheral Neuropathy Treatment Market Research Report
By Type
Antimunocel, ASP-8477, BNV-222, Capsaicin, CBX-129801, Others
By Application
Hospital, Clinic, Others
By Companies
Achelios Therapeutics Inc, Celgene Corp, Commence Bio Inc, Grunenthal GmbH, Immune Pharmaceuticals Inc, KPI Therapeutics Inc, Medifron DBT Co Ltd, Mitsubishi Tanabe Pharma Corp, Novaremed Ltd, Reata Pharmaceuticals Inc, Relief Therapeutics Holding AG, ViroMed Co Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Diabetic Peripheral Neuropathy Treatment Market Report Segments:
The global Diabetic Peripheral Neuropathy Treatment market is segmented on the basis of:
Types
Antimunocel, ASP-8477, BNV-222, Capsaicin, CBX-129801, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Achelios Therapeutics Inc
- Celgene Corp
- Commence Bio Inc
- Grunenthal GmbH
- Immune Pharmaceuticals Inc
- KPI Therapeutics Inc
- Medifron DBT Co Ltd
- Mitsubishi Tanabe Pharma Corp
- Novaremed Ltd
- Reata Pharmaceuticals Inc
- Relief Therapeutics Holding AG
- ViroMed Co Ltd
Highlights of The Diabetic Peripheral Neuropathy Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antimunocel
- ASP-8477
- BNV-222
- Capsaicin
- CBX-129801
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diabetic Peripheral Neuropathy Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best treatment for diabetic peripheral neuropathy will vary depending on the individual's specific symptoms and diagnosis. However, some common treatments for diabetic peripheral neuropathy include:nnu2022 Physical therapy: This may help improve range of motion and strength in the legs and feet, which can help reduce pain and disability.nu2022 Anti-inflammatory medications: These medications may help reduce inflammation in the nerves, which can lead to improved nerve function.nu2022 Pain relief medication: Many people find that prescription painkillers or over-the-counter remedies such as ibuprofen are helpful in relieving their symptoms of diabetic peripheral neuropathy.
Some of the major companies in the diabetic peripheral neuropathy treatment market are Achelios Therapeutics Inc, Celgene Corp, Commence Bio Inc, Grunenthal GmbH, Immune Pharmaceuticals Inc, KPI Therapeutics Inc, Medifron DBT Co Ltd, Mitsubishi Tanabe Pharma Corp, Novaremed Ltd, Reata Pharmaceuticals Inc, Relief Therapeutics Holding AG, ViroMed Co Ltd.
The diabetic peripheral neuropathy treatment market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Diabetic Peripheral Neuropathy Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Diabetic Peripheral Neuropathy Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Diabetic Peripheral Neuropathy Treatment Market - Supply Chain
4.5. Global Diabetic Peripheral Neuropathy Treatment Market Forecast
4.5.1. Diabetic Peripheral Neuropathy Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Diabetic Peripheral Neuropathy Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Diabetic Peripheral Neuropathy Treatment Market Absolute $ Opportunity
5. Global Diabetic Peripheral Neuropathy Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Type
5.3.1. Antimunocel
5.3.2. ASP-8477
5.3.3. BNV-222
5.3.4. Capsaicin
5.3.5. CBX-129801
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Diabetic Peripheral Neuropathy Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Diabetic Peripheral Neuropathy Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Diabetic Peripheral Neuropathy Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Diabetic Peripheral Neuropathy Treatment Demand Share Forecast, 2019-2026
9. North America Diabetic Peripheral Neuropathy Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Type
9.7.1. Antimunocel
9.7.2. ASP-8477
9.7.3. BNV-222
9.7.4. Capsaicin
9.7.5. CBX-129801
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Diabetic Peripheral Neuropathy Treatment Demand Share Forecast, 2019-2026
10. Latin America Diabetic Peripheral Neuropathy Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Type
10.7.1. Antimunocel
10.7.2. ASP-8477
10.7.3. BNV-222
10.7.4. Capsaicin
10.7.5. CBX-129801
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Diabetic Peripheral Neuropathy Treatment Demand Share Forecast, 2019-2026
11. Europe Diabetic Peripheral Neuropathy Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Type
11.7.1. Antimunocel
11.7.2. ASP-8477
11.7.3. BNV-222
11.7.4. Capsaicin
11.7.5. CBX-129801
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Diabetic Peripheral Neuropathy Treatment Demand Share, 2019-2026
12. Asia Pacific Diabetic Peripheral Neuropathy Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Type
12.7.1. Antimunocel
12.7.2. ASP-8477
12.7.3. BNV-222
12.7.4. Capsaicin
12.7.5. CBX-129801
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Diabetic Peripheral Neuropathy Treatment Demand Share, 2019-2026
13. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Market Size and Volume Forecast by Type
13.7.1. Antimunocel
13.7.2. ASP-8477
13.7.3. BNV-222
13.7.4. Capsaicin
13.7.5. CBX-129801
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Diabetic Peripheral Neuropathy Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Diabetic Peripheral Neuropathy Treatment Market: Market Share Analysis
14.2. Diabetic Peripheral Neuropathy Treatment Distributors and Customers
14.3. Diabetic Peripheral Neuropathy Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Achelios Therapeutics Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Celgene Corp
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Commence Bio Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Grunenthal GmbH
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Immune Pharmaceuticals Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. KPI Therapeutics Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Medifron DBT Co Ltd
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mitsubishi Tanabe Pharma Corp
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novaremed Ltd
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Reata Pharmaceuticals Inc
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Relief Therapeutics Holding AG
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. ViroMed Co Ltd
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
